| Q40525805 | Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection |
| Q37417520 | Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study |
| Q36642119 | Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection |
| Q47139711 | Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis. |
| Q57495788 | Hospitalization Outcomes in Pneumocystis Pneumonia Inpatient Population: A Comparison between HIV and Non-HIV Patients |
| Q33768267 | Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: A Retrospective Cohort Study |
| Q35270593 | Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients |
| Q35793693 | Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death |
| Q48149271 | Pneumocystis Pneumonia in Solid-Organ Transplant Recipients |
| Q47709380 | Pneumocystosis in dogs: meta-analysis of 43 published cases including clinical signs, diagnostic procedures, and treatment |
| Q83183740 | Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases |
| Q41708606 | Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis |
| Q36604807 | Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma |